Avory & Company LLC Has $7.27 Million Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

Avory & Company LLC increased its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 25.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 193,162 shares of the company's stock after buying an additional 39,386 shares during the period. Omnicell accounts for approximately 5.1% of Avory & Company LLC's portfolio, making the stock its 9th largest holding. Avory & Company LLC owned approximately 0.42% of Omnicell worth $7,269,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Omnicell by 15.1% in the third quarter. Vanguard Group Inc. now owns 5,137,084 shares of the company's stock valued at $231,374,000 after acquiring an additional 674,824 shares during the last quarter. Pacer Advisors Inc. grew its stake in shares of Omnicell by 321,488.8% during the fourth quarter. Pacer Advisors Inc. now owns 1,058,027 shares of the company's stock valued at $39,814,000 after buying an additional 1,057,698 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Omnicell by 3.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 638,646 shares of the company's stock valued at $24,032,000 after buying an additional 19,601 shares during the last quarter. Exchange Traded Concepts LLC boosted its holdings in shares of Omnicell by 48.2% during the fourth quarter. Exchange Traded Concepts LLC now owns 566,704 shares of the company's stock worth $21,325,000 after purchasing an additional 184,213 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in shares of Omnicell by 12,425.6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 482,488 shares of the company's stock worth $21,731,000 after purchasing an additional 478,636 shares during the period. Institutional investors own 97.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on OMCL. Wells Fargo & Company dropped their target price on shares of Omnicell from $28.00 to $26.00 and set an "equal weight" rating for the company in a report on Friday, February 9th. Barclays began coverage on shares of Omnicell in a report on Wednesday, January 3rd. They set an "underweight" rating and a $33.00 target price for the company. Finally, Benchmark reiterated a "buy" rating and set a $38.00 target price on shares of Omnicell in a report on Tuesday. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $42.20.

Omnicell Stock Down 2.2 %

OMCL traded down $0.59 on Tuesday, hitting $26.81. The company had a trading volume of 482,757 shares, compared to its average volume of 536,661. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.52 and a quick ratio of 2.22. Omnicell, Inc. has a 52-week low of $25.69 and a 52-week high of $77.14. The stock has a fifty day simple moving average of $27.61 and a 200-day simple moving average of $31.93. The firm has a market capitalization of $1.23 billion, a P/E ratio of -59.58 and a beta of 0.76.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Thursday, February 8th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.22. Omnicell had a negative net margin of 1.78% and a positive return on equity of 3.43%. The firm had revenue of $258.85 million during the quarter, compared to analyst estimates of $256.00 million. As a group, equities analysts expect that Omnicell, Inc. will post 0.09 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.